PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Prothena Corporation’s Phase III AFFIRM-AL trial of birtamimab in individuals with amyloid light-chain (AL) amyloidosis ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Prothena (PRTA) stock drops as a late-stage trial for the company's lead candidate fails, prompting Oppenheimer and Jefferies ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for ...

At St. Clair Health, a community health system in Pittsburgh, where Dr. Pray was working to build up an organized heart ...

In partnership with the Silicon Valley Business Journal, we'll honor the Bay Area's top companies recognized as the Best ...

What: Erlanger Trauma Services will host its annual Trauma Symposium at the Chattanooga Convention Center on Thursday, May 22 ...

Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the ...